Stay updated on Nivolumab for Peripheral T-cell Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page.

Latest updates to the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe clinical trial record for nivolumab in relapsed or refractory peripheral T-cell lymphoma is displayed instead of an access-denied error. It includes study details and results, eligibility criteria, and a study protocol document.SummaryDifference62%

- Check17 days agoChange DetectedThe ClinicalTrials.gov site revision displayed in the footer changed from v3.7.2 to v3.8.0.SummaryDifference0.2%

- Check24 days agoChange DetectedA banner announces an NIH website transition and says “Super Intelligence” will replace “Artificial Intelligence” in agency content during the transition.SummaryDifference1%

- Check31 days agoChange DetectedThe ClinicalTrials.gov page remains a 403 Forbidden error page; its footer revision changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check38 days agoChange DetectedThe footer revision identifier changes from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check59 days agoChange DetectedA 403 Forbidden page is now displayed, replacing the study record content. The site header and footer remain visible, signaling an access/permission issue rather than a substantive study data update.SummaryDifference20%

Stay in the know with updates to Nivolumab for Peripheral T-cell Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for Peripheral T-cell Lymphoma Clinical Trial page.